Does the JUPITER trial mean I should be on a statin if my hs-CRP is high even though my LDL is normal?

The JUPITER trial enrolled exactly this population, men with LDL below 130 mg/dL and hs-CRP at or above 2.0 mg/L, and found a 44% reduction in major adverse cardiovascular events with rosuvastatin. The trial was stopped early due to overwhelming benefit. So yes, elevated hs-CRP with normal-to-borderline LDL is now a recognized indication for statin consideration, and this is reflected in the current ACC/AHA guidelines, which list hs-CRP above 2.0 mg/L as a risk-enhancing factor that strengthens the indication for statin therapy in the intermediate-risk range.

This does not mean every man with hs-CRP above 2.0 mg/L should automatically be on a statin. The decision requires integrating hs-CRP with your full ASCVD risk calculation: your ApoB, blood pressure, family history, smoking status, age, and the severity of the elevation. A 38-year-old with hs-CRP of 2.2 mg/L and no other risk factors has a different calculation than a 51-year-old with hs-CRP of 3.6, a family history of MI at 55, and an ApoB of 130 mg/dL. The JUPITER finding is real. Its application requires the full risk picture. (Ridker et al., NEJM, 2008)

Cardiologist's calibrated position, Solid (1) for the JUPITER finding. Promising (2) for statin therapy as appropriate for all men with elevated hs-CRP and intermediate-to-high ASCVD risk.

What to do: Bring your hs-CRP result and the JUPITER trial reference to your physician. Ask specifically how your hs-CRP changes your ASCVD risk calculation and whether the ACC/AHA risk-enhancing factor criteria now indicate statin therapy for you.

For the full picture, read Inflammation's Invoice.